Takeda

Therapeutic Focus - Vaccines | Takeda Pharmaceuticals

Vaccines

woman looking through microscope

For more than 70 years, we have supplied routine vaccines to help protect the health of people in Japan including for measles, rubella and mumps. Today, we're expanding our global vaccine business by relying on innovation to tackle some of the world's most challenging infectious diseases, such as dengue, COVID-19 and pandemic influenza.

Our team brings an outstanding track record and a wealth of knowledge in global vaccine development and manufacturing to advance a pipeline of vaccines to help address some of the most pressing public health needs.

Our mission is to develop and deliver innovative vaccines that tackle some of the more challenging problems in public health and help improve the health of people around the world.

Disease areas

Dengue

  • A mosquito-borne disease that continues to spread around the world.4

  • Estimated that half of the world's population is at risk of dengue infection.4

COVID-19

  • Caused by a new coronavirus, SARS-CoV-2, first identified in December of 2019.5

  • COVID-19 cases have been identified worldwide.6

Pandemic Influenza

  • Influenza viruses are constantly changing, making it possible for them to infect people and easily spread on rare occasions.7

  • Last three pandemics killed approximately 1.1 million (1957), 1 million (1968) and 0.2-0.6 million (2009) people.8,9,10

The value of vaccination

  • Vaccines prevent 3.5 to 5 million deaths each year and have transformed global public health.1

  • Vaccines are one of the most cost-effective ways to save lives.2

  • 50 million deaths can be prevented through immunization between 2021 and 2030.3

Related content

Our Stories